urea has been researched along with Psychoses in 84 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a trial that was stopped early for efficacy, patients with dementia-related psychosis who had a response to pimavanserin had a lower risk of relapse with continuation of the drug than with discontinuation." | 9.41 | Trial of Pimavanserin in Dementia-Related Psychosis. ( Ballard, C; Cummings, JL; Devanand, DP; Erten-Lyons, D; Foff, EP; McEvoy, B; Soto-Martin, ME; Stankovic, S; Sultzer, DL; Tariot, PN; Weintraub, D; Youakim, JM, 2021) |
| "Patients with ADP, who show improvement in psychotic symptoms after pimavanserin treatment, also experience an improvement in concomitant agitation and aggression." | 9.34 | Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis. ( Abler, V; Ballard, CG; Coate, B; Foff, E; Stankovic, S, 2020) |
| "This study provides Class II evidence that in patients with Parkinson disease who are 65 or older and residing in Medicare-certified long-term care facilities, pimavanserin is associated with an increased risk of 30-day hospitalization and higher 90-, 180-, and 365-day mortality." | 8.02 | Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease. ( Alexander, GC; An, H; Hwang, YJ; Mehta, HB; Moore, TJ, 2021) |
| " Controlled studies comparing clozapine and pimavanserin in refractory schizophrenia are warranted to confirm these clinical observations." | 7.91 | Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. ( Fedora, R; Morton, R; Nasrallah, HA, 2019) |
| "Pimavanserin is a first-in-class selective serotonin 5-HT2A receptor inverse agonist approved for the treatment of Parkinson disease psychosis." | 7.91 | Can pimavanserin help patients with Parkinson disease psychosis? ( Canal, C; de la Cruz, J, 2019) |
| "Pimavanserin may prove beneficial in treating the hallucinations and delusions of DRP without worsening cognitive or motor function." | 6.82 | Dementia-related psychosis and the potential role for pimavanserin. ( Cummings, JL; Devanand, DP; Stahl, SM, 2022) |
| "Psychosis is common across dementia types with a prevalence of 20% to 70%." | 6.58 | Pimavanserin: Potential Treatment For Dementia-Related Psychosis. ( Ballard, C; Cummings, J; Foff, E; Norton, J; Owen, R; Stankovic, S; Tariot, P; Youakim, J, 2018) |
| "In a trial that was stopped early for efficacy, patients with dementia-related psychosis who had a response to pimavanserin had a lower risk of relapse with continuation of the drug than with discontinuation." | 5.41 | Trial of Pimavanserin in Dementia-Related Psychosis. ( Ballard, C; Cummings, JL; Devanand, DP; Erten-Lyons, D; Foff, EP; McEvoy, B; Soto-Martin, ME; Stankovic, S; Sultzer, DL; Tariot, PN; Weintraub, D; Youakim, JM, 2021) |
| "Patients with ADP, who show improvement in psychotic symptoms after pimavanserin treatment, also experience an improvement in concomitant agitation and aggression." | 5.34 | Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis. ( Abler, V; Ballard, CG; Coate, B; Foff, E; Stankovic, S, 2020) |
| " Participants were receiving 40 mg pimavanserin daily in addition to concurrent antipsychotics and Parkinson disease medications." | 5.20 | Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. ( Ballard, C; Burn, DJ; Coate, B; Corbett, A; Isaacson, S; Mills, R; Pahwa, R; Rascol, O; Williams, H, 2015) |
| " Pimavanserin is the first FDA approved drug for the treatment of hallucinations and delusions associated with PDP." | 4.95 | Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. ( Kianirad, Y; Simuni, T, 2017) |
| "Pimavanserin was approved in April 2016 for the treatment of delusions and hallucinations of PDP." | 4.95 | Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis. ( Bozymski, KM; Crouse, EL; Gatesman, TL; Lowe, DK; Pasternak, KM, 2017) |
| "Although there are no approved drugs for treating psychotic symptoms in any of the movement disorders, pimavanserin, a 5-HT2A inverse agonist, is thought likely to gain approval in 2015 for treating PD psychosis." | 4.90 | Treating psychosis in movement disorder patients: a review. ( Borek, LL; Friedman, JH, 2014) |
| " Mortality analyses were adjusted for age, sex, levodopa equivalent daily dose (LEDD), and dementia." | 4.31 | Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis. ( Alakkas, A; Liu, L; Longardner, K; Nahab, FB; Wright, BA; Xu, R; You, H, 2023) |
| "This study provides Class II evidence that in patients with Parkinson disease who are 65 or older and residing in Medicare-certified long-term care facilities, pimavanserin is associated with an increased risk of 30-day hospitalization and higher 90-, 180-, and 365-day mortality." | 4.02 | Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease. ( Alexander, GC; An, H; Hwang, YJ; Mehta, HB; Moore, TJ, 2021) |
| " Controlled studies comparing clozapine and pimavanserin in refractory schizophrenia are warranted to confirm these clinical observations." | 3.91 | Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. ( Fedora, R; Morton, R; Nasrallah, HA, 2019) |
| "Pimavanserin is a first-in-class selective serotonin 5-HT2A receptor inverse agonist approved for the treatment of Parkinson disease psychosis." | 3.91 | Can pimavanserin help patients with Parkinson disease psychosis? ( Canal, C; de la Cruz, J, 2019) |
| "Dementia due to Parkinson's disease and Alzheimer's disease are associated with behavioural and psychological symptoms, including psychosis." | 3.01 | Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosis. ( Isaacson, SH; Pagan, F; Pahwa, R; Sabbagh, M; Small, GW; Torres-Yaghi, Y, 2023) |
| "Pimavanserin has a unique mechanism of action." | 3.01 | A New Hope in Alzheimer's Disease Psychosis: Pimavanserin. ( Akın, M; Kurhan, F, 2023) |
| "Pimavanserin is a 5-HT2A receptor inverse agonist/antagonist and is approved in the United States for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis." | 2.90 | Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. ( Ballard, C; Coate, B; Stankovic, S; Youakim, JM, 2019) |
| "PD psychosis is often associated with cognitive impairment, including dementia, and involves dopaminergic, serotonergic, and cholinergic mechanisms." | 2.87 | Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. ( Andersson, C; Ballard, C; Coate, B; Espay, AJ; Factor, SA; Fredericks, D; Friedman, JH; Guskey, MT; Lang, AE; Larsen, NJ; Norton, JC; Vizcarra, JA; Weintraub, D, 2018) |
| "The terms "Parkinson's disease psychosis", "Parkinson psychosis," "neurodegenerative psychosis", and "dopamine psychosis" were among the keywords used in the search." | 2.82 | Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments. ( Bautista-Sandoval, MJ; Bermúdez, V; Chacín, M; Chávez-Castillo, M; Cudris-Torres, L; Duran, P; Medina-Ortiz, O; Ortega, Á; Palmar, J; Riaño-Garzón, M; Rojas, M; Salazar, J, 2022) |
| "Pimavanserin may prove beneficial in treating the hallucinations and delusions of DRP without worsening cognitive or motor function." | 2.82 | Dementia-related psychosis and the potential role for pimavanserin. ( Cummings, JL; Devanand, DP; Stahl, SM, 2022) |
| "Pimavanserin may benefit patients with Parkinson's disease psychosis for whom few other treatment options exist." | 2.79 | Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. ( Ballard, C; Chi-Burris, K; Corbett, A; Cummings, J; Dhall, R; Isaacson, S; Mills, R; Williams, H, 2014) |
| "There is a considerable overlap between Parkinson's Disease Dementia (PDD) and Dementia with Lewy Bodies (DLB)." | 2.66 | Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review. ( Bronstein, JM; Kyle, K, 2020) |
| "Pimavanserin is a receptor antagonist (5-HT2A, 5-HT2C) that has been given market authorization for psychosis occurring in Parkinson's disease." | 2.66 | New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin. ( Cannavò, D; Caraci, F; Caruso, G; Drago, F; Leggio, GM; Salomone, S; Santagati, M, 2020) |
| "Psychosis is a common problem for people treated for Parkinson's disease." | 2.58 | Pharmacological interventions for psychosis in Parkinson's disease patients. ( Friedman, JH, 2018) |
| "Psychosis is common across dementia types with a prevalence of 20% to 70%." | 2.58 | Pimavanserin: Potential Treatment For Dementia-Related Psychosis. ( Ballard, C; Cummings, J; Foff, E; Norton, J; Owen, R; Stankovic, S; Tariot, P; Youakim, J, 2018) |
| "We discuss features of Parkinson's disease psychosis (PDP) including symptomology and pathophysiology." | 2.58 | Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis. ( Ondo, WG; Panchal, SC, 2018) |
| "Patients with Parkinson's disease psychosis (PDP) are often treated with an atypical antipsychotic, especially quetiapine or clozapine, but side effects, lack of sufficient efficacy, or both may motivate a switch to pimavanserin, the first medication approved for management of PDP." | 2.58 | Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. ( Adler, CH; Alva, G; Black, KJ; Cooney, JW; Isaacson, S; Kremens, D; Menza, MA; Meyer, JM; Morrissette, DA; Nasrallah, H; Pahwa, R; Patkar, AA; Simuni, T; Stacy, M; Stahl, SM, 2018) |
| "Psychosis is highly prevalent in PD patients and is associated with poor prognosis." | 2.53 | Pimavanserin for the treatment of Parkinson's disease psychosis. ( Chendo, I; Ferreira, JJ, 2016) |
| "Pimavanserin (ACP-103) is a selective inverse agonist of the 5-hydroxytryptamine 2A (5-HT2A) receptor intended to treat patients with Parkinson's disease psychosis (PDP)." | 2.52 | Pimavanserin. ( Anderson, KC; Cox, A; Hunter, NS, 2015) |
| "Pimavanserin displays nanomolar potency as a 5-HT2A receptor inverse agonist, selectivity for 5-HT2A over 5-HT2C receptors, and no meaningful activity at any other G-protein coupled receptor." | 2.50 | On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. ( Burstein, ES; Hacksell, U; McFarland, K; Mills, RG; Williams, H, 2014) |
| " Safety was evaluated from adverse events (AEs), clinical laboratory results, motor symptoms, electrocardiograms (ECG), and mortality." | 1.56 | Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis. ( Abler, V; Azulay, JP; Ballard, CG; Demos, G; Fernandez, HH; Ferreira, JJ; Ilic, TV; Isaacson, S; Kreitzman, DL; Liu, IY; Norton, JC; Stankovic, S, 2020) |
| "Psychosis is common among patients with Parkinson's disease (PD) and dementia with Lewy bodies (DLB)." | 1.51 | Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. ( Dahodwala, N; Horn, S; Richardson, H; Weintraub, D; Xie, SX, 2019) |
| "Psychosis is common in Parkinson's disease-related disorders and is associated with significant morbidity." | 1.51 | Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review. ( Claassen, DO; Darby, RR; Farooque, A; Sellers, J, 2019) |
| "Psychotic disorders in Parkinson's disease (PDPD) are common and significantly influence the quality of life and disability level." | 1.43 | [Modern approaches to treatment of psychosis in Parkinson's disease]. ( Cozac, VV, 2016) |
| "Pimavanserin is an inverse agonist at the 5HT2A receptor, with a lower binding affinity at the serotonin-2C receptor and sigma 1 receptor, but no significant binding to dopamine or other receptors." | 1.43 | Pimavanserin: An Inverse Agonist Antipsychotic Drug. ( Howland, RH, 2016) |
| "Treatment with pimavanserin, a selective serotonin 5-HT(2A) receptor inverse agonist, prevented 2,5-dimethoxy-4-iodoamphetamine hydrochloride-induced head twitches, reversed the augmented locomotor response to amphetamine, and normalized prepulse inhibition in mice with amyloid pathology." | 1.38 | Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease. ( Bonhaus, DW; McFarland, K; Price, DL, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (9.52) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.19) | 29.6817 |
| 2010's | 48 (57.14) | 24.3611 |
| 2020's | 27 (32.14) | 2.80 |
| Authors | Studies |
|---|---|
| Tariot, PN | 2 |
| Ballard, C | 8 |
| Devanand, DP | 3 |
| Cummings, JL | 3 |
| Sultzer, DL | 2 |
| Crump, CJ | 1 |
| Litteral, CA | 1 |
| Elsayed, OH | 1 |
| El-Mallakh, RS | 1 |
| Ma, M | 1 |
| Yang, Y | 1 |
| Du, G | 1 |
| Dai, Y | 1 |
| Zhu, X | 1 |
| Wang, W | 1 |
| Xu, H | 1 |
| Zhang, J | 1 |
| Zheng, L | 1 |
| Zou, F | 1 |
| Yang, H | 1 |
| Liu, B | 1 |
| Liu, W | 1 |
| Ye, L | 1 |
| Zhang, R | 1 |
| Tian, J | 1 |
| Sabbagh, M | 1 |
| Small, GW | 1 |
| Isaacson, SH | 3 |
| Torres-Yaghi, Y | 1 |
| Pagan, F | 2 |
| Pahwa, R | 3 |
| Mosholder, AD | 1 |
| Ma, Y | 1 |
| Akhtar, S | 1 |
| Podskalny, GD | 1 |
| Feng, Y | 1 |
| Lyu, H | 1 |
| Liao, J | 1 |
| Wei, Y | 1 |
| Wernecke, M | 1 |
| Leishear, K | 1 |
| Nelson, LM | 1 |
| MaCurdy, TE | 1 |
| Kelman, JA | 1 |
| Graham, DJ | 1 |
| Colijn, MA | 1 |
| Schneider, LS | 2 |
| Rojas, M | 1 |
| Chávez-Castillo, M | 1 |
| Duran, P | 1 |
| Ortega, Á | 1 |
| Bautista-Sandoval, MJ | 1 |
| Salazar, J | 1 |
| Riaño-Garzón, M | 1 |
| Chacín, M | 1 |
| Medina-Ortiz, O | 1 |
| Palmar, J | 1 |
| Cudris-Torres, L | 1 |
| Bermúdez, V | 1 |
| Ntalkitsi, S | 2 |
| Efthymiou, D | 2 |
| Bozikas, V | 2 |
| Vassilopoulou, E | 2 |
| Longardner, K | 1 |
| Wright, BA | 1 |
| Alakkas, A | 1 |
| You, H | 1 |
| Xu, R | 1 |
| Liu, L | 1 |
| Nahab, FB | 2 |
| Albujuq, NR | 1 |
| Meana, JJ | 1 |
| Diez-Alarcia, R | 1 |
| Muneta-Arrate, I | 1 |
| Naqvi, A | 1 |
| Althumayri, K | 1 |
| Alsehli, M | 1 |
| Kurhan, F | 1 |
| Akın, M | 1 |
| Horn, S | 1 |
| Richardson, H | 1 |
| Xie, SX | 1 |
| Weintraub, D | 3 |
| Dahodwala, N | 1 |
| Morelhão, PK | 1 |
| Dokkedal-Silva, V | 1 |
| Galduróz, JCF | 1 |
| Tufik, S | 1 |
| Andersen, ML | 1 |
| Mansuri, Z | 1 |
| Patel, K | 1 |
| Desai, R | 1 |
| Zafar, MK | 1 |
| Jain, S | 1 |
| Kyle, K | 2 |
| Bronstein, JM | 2 |
| Jukić, MM | 1 |
| Caraci, F | 1 |
| Santagati, M | 1 |
| Caruso, G | 1 |
| Cannavò, D | 1 |
| Leggio, GM | 1 |
| Salomone, S | 1 |
| Drago, F | 1 |
| Ballard, CG | 3 |
| Kreitzman, DL | 2 |
| Isaacson, S | 4 |
| Liu, IY | 1 |
| Norton, JC | 5 |
| Demos, G | 3 |
| Fernandez, HH | 2 |
| Ilic, TV | 2 |
| Azulay, JP | 2 |
| Ferreira, JJ | 3 |
| Abler, V | 3 |
| Stankovic, S | 8 |
| Coate, B | 7 |
| Norton, J | 2 |
| Foff, E | 2 |
| Stahl, SM | 4 |
| Soto-Martin, ME | 1 |
| Erten-Lyons, D | 1 |
| McEvoy, B | 1 |
| Youakim, JM | 3 |
| Foff, EP | 1 |
| Friedman, JI | 1 |
| Ali, F | 1 |
| Hwang, YJ | 1 |
| Alexander, GC | 1 |
| An, H | 1 |
| Moore, TJ | 1 |
| Mehta, HB | 1 |
| Liu, KY | 1 |
| Howard, R | 1 |
| Bozymski, KM | 1 |
| Lowe, DK | 1 |
| Pasternak, KM | 1 |
| Gatesman, TL | 1 |
| Crouse, EL | 1 |
| Wilby, KJ | 1 |
| Johnson, EG | 1 |
| Johnson, HE | 1 |
| Ensom, MHH | 1 |
| Cozac, VV | 1 |
| Hermanowicz, N | 2 |
| Alva, G | 2 |
| Espay, AJ | 2 |
| Patel, A | 1 |
| Madrid, KC | 1 |
| Kremens, D | 2 |
| Kenney, J | 1 |
| Arquette, S | 1 |
| Tereso, G | 1 |
| Lopes, M | 1 |
| Farnum, C | 1 |
| Yuan, M | 1 |
| Sperry, L | 1 |
| Malhado-Chang, N | 1 |
| Duffy, A | 1 |
| Wheelock, V | 1 |
| Farias, S | 1 |
| O'Connor, K | 1 |
| Olichney, J | 1 |
| Shahlaie, K | 1 |
| Zhang, L | 1 |
| Fredericks, D | 2 |
| Atchison, C | 1 |
| Schoenhaus, R | 1 |
| Pill, MW | 1 |
| Kianirad, Y | 1 |
| Simuni, T | 2 |
| Sahli, ZT | 1 |
| Tarazi, FI | 1 |
| Citrome, L | 2 |
| Chi-Burris, K | 2 |
| Panchal, SC | 1 |
| Ondo, WG | 1 |
| Banister, C | 1 |
| Khan, Z | 1 |
| Cummings, J | 3 |
| Owen, R | 2 |
| Friedman, JH | 5 |
| Schubmehl, S | 1 |
| Sussman, J | 1 |
| Moreno, GM | 1 |
| Gandhi, R | 1 |
| Lessig, SL | 1 |
| Wright, B | 1 |
| Litvan, I | 1 |
| Tariot, P | 1 |
| Youakim, J | 1 |
| Guskey, MT | 1 |
| Vizcarra, JA | 1 |
| Factor, SA | 1 |
| Lang, AE | 1 |
| Larsen, NJ | 1 |
| Andersson, C | 1 |
| Black, KJ | 1 |
| Nasrallah, H | 1 |
| Stacy, M | 1 |
| Adler, CH | 1 |
| Cooney, JW | 1 |
| Menza, MA | 1 |
| Meyer, JM | 1 |
| Patkar, AA | 1 |
| Morrissette, DA | 1 |
| de la Cruz, J | 1 |
| Canal, C | 1 |
| Nasrallah, HA | 1 |
| Fedora, R | 1 |
| Morton, R | 1 |
| Sellers, J | 1 |
| Darby, RR | 1 |
| Farooque, A | 1 |
| Claassen, DO | 1 |
| Mohanty, D | 1 |
| Sarai, S | 1 |
| Naik, S | 1 |
| Lippmann, S | 1 |
| Hubbard, D | 1 |
| Hacksell, U | 2 |
| McFarland, K | 4 |
| Mills, R | 3 |
| Williams, H | 4 |
| Corbett, A | 2 |
| Dhall, R | 1 |
| Fox, SH | 1 |
| Kingwell, K | 1 |
| Burstein, ES | 1 |
| Mills, RG | 1 |
| Borek, LL | 1 |
| Rascol, O | 1 |
| Burn, DJ | 1 |
| Hunter, NS | 1 |
| Anderson, KC | 1 |
| Cox, A | 1 |
| Howland, RH | 1 |
| Chendo, I | 1 |
| Majlath, Z | 1 |
| Obal, I | 1 |
| Vecsei, L | 1 |
| Samudra, N | 1 |
| Patel, N | 1 |
| Womack, KB | 1 |
| Khemani, P | 1 |
| Chitnis, S | 1 |
| Meltzer, HY | 1 |
| Revell, S | 1 |
| Johnson, A | 1 |
| Bahr, D | 1 |
| Milella, MS | 1 |
| Passarelli, F | 1 |
| De Carolis, L | 1 |
| Schepisi, C | 1 |
| Nativio, P | 1 |
| Scaccianoce, S | 1 |
| Nencini, P | 1 |
| Price, DL | 2 |
| Bonhaus, DW | 2 |
| VOELKEL, A | 1 |
| ELSASSER, G | 1 |
| BRUNE, GG | 1 |
| HOHL, HH | 1 |
| HIMWICH, HE | 1 |
| FAHRNI, R | 1 |
| BARUCCI, M | 1 |
| Vanover, KE | 1 |
| Robbins-Weilert, D | 1 |
| Wilbraham, DG | 1 |
| Mant, TG | 1 |
| van Kammen, DP | 1 |
| Davis, RE | 1 |
| Weiner, DM | 1 |
| Stenbäck, A | 1 |
| Haapanen, E | 1 |
| Hoffet, H | 1 |
| Lagatz, WH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis[NCT03325556] | Phase 3 | 392 participants (Actual) | Interventional | 2017-09-27 | Completed | ||
| Evidence-Based Supported Digital Intervention for Improving Wellbeing and Health of People Living in Care Homes and Care Home Staff (WHELD) During COVID-19: An RCT to Evaluate COVID-19 Adapted E-WHELD: Benefits and Cost-Effectiveness[NCT04590469] | 2,880 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | |||
| A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease[NCT02035553] | Phase 2 | 181 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease[NCT01174004] | Phase 3 | 199 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease[NCT00550238] | Phase 3 | 459 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The endpoint of time from randomization to discontinuation from the DB period for any reason (other than termination of the study by the sponsor) was compared between treatment groups using a Cox regression model. The treatment effect was measured by the HR. (NCT03325556)
Timeframe: From randomization in the DB period through 26 weeks
| Intervention | days (Median) |
|---|---|
| Pimavanserin Double-Blind Period | NA |
| Placebo Double-Blind Period | NA |
"The time from randomization to relapse in the DB period was compared between treatment groups using a Cox regression model. The treatment effect was measured by the hazard ratio (HR).~Relapse was defined as (1) ≥30% increase in SAPS-H+D total score from DB baseline (BL) and CGI-I score ≥6 relative to DB BL, (2) treatment with antipsychotic for dementia-related delusions/hallucinations, (3) treatment/study discontinuation due to lack of efficacy, and/or (4) hospitalization for worsening dementia-related psychosis.~SAPS-H+D is a 20-item scale; the total score is the sum of the 20 item scores (range 0-100); higher scores denote more severe symptoms. CGI-I is a clinician-rated 7-point scale to rate improvement in hallucinations/delusions relative to BL (range 1-7); higher scores denote less improvement or worsening.~A pre-specified IA was conducted after accrual of 40 adjudicated relapse events. The prespecified stopping criterion was met; the study was stopped for efficacy." (NCT03325556)
Timeframe: From randomization in the DB period through 26 weeks
| Intervention | days (Median) |
|---|---|
| Pimavanserin Double-Blind Period | NA |
| Placebo Double-Blind Period | NA |
Change from Baseline to Day 43 in the Neuropsychiatric Inventory-Nursing Home Version (NPI-NH) psychosis score (Delusions [Domain A]+Hallucinations [Domain B]) in the Full Analysis Set (FAS). The NPI-NH is a questionnaire that quantifies behavioral changes in dementia in nursing home patients and evaluates 12 behavioral domains. For each of the 12 behavioral domains the Frequency (scale:1=occasionally to 4=very frequently) is multiplied by the Severity (scale:1=Mild to 3=Severe) to obtain a domain score (frequency x severity), The NPI-NH Psychosis Subscale consists of the two domains of Delusions and Hallucinations, calculated by adding the Individual domain scores, to yield a possible total score of 0 to 24. Lower scores correspond to less severity. A negative change score from baseline indicates improvement. (NCT02035553)
Timeframe: Day 43
| Intervention | Score on the NPI-NH scale (Least Squares Mean) |
|---|---|
| Placebo | -1.93 |
| Pimavanserin 40 mg | -3.76 |
"Antipsychotic Efficacy was defined as a decrease in the severity and/or frequency of hallucinations and/or delusions. This is measured as the change from baseline (Day 1) to Day 43 in the Scale for the Assessment of Positive Symptoms 9-item sum score for Parkinson's Disease (SAPS-PD). The possible total score is 0 to 45 and a negative change in score indicates improvement.~Analysis Method: Mixed Model Repeated Measures (MMRM)" (NCT01174004)
Timeframe: Each study visit (i.e. Days 1, 15, 29 and 43)
| Intervention | Score on the SAPS-PD scale (Least Squares Mean) | |
|---|---|---|
| Change from Baseline | Difference of Least Squares Mean versus Placebo | |
| Pimavanserin 40 mg | -5.79 | -3.06 |
| Placebo | -2.73 | NA |
"Motor symptoms were measured using the change from baseline to Day 43 in the combined score of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) and Part III (Motor Examination). The possible total score is 0 to 160 and a negative change in score indicates improvement.~Analysis Method: Analysis of Covariance (ANCOVA). The UPDRS Parts II+III score was analyzed by constructing 2-sided 95% confidence intervals (CIs) on the difference between the pimavanserin dose group and placebo mean change from baseline. Non-inferiority was concluded if the upper limit of the CI was less than or equal to 5." (NCT01174004)
Timeframe: Study Days 1 and 43
| Intervention | Score on the UPDRS-II+III (Least Squares Mean) | |
|---|---|---|
| Change from Baseline | Difference of Least Squares Mean versus Placebo | |
| Pimavanserin 40 mg | -1.40 | 0.29 |
| Placebo | -1.69 | NA |
Number (%) of patients with drug-related treatment-emergent AEs (i.e. AEs reported by the Investigator as possibly, probably, or highly probably related to study drug) (NCT00550238)
Timeframe: From first to last study drug dose plus 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Pimavanserin | 180 |
23 reviews available for urea and Psychoses
| Article | Year |
|---|---|
Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosis.
Topics: Alzheimer Disease; Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders | 2023 |
Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments.
Topics: Antipsychotic Agents; Dopamine; Hallucinations; Humans; Illusions; Parkinson Disease; Psychotic Diso | 2022 |
A New Hope in Alzheimer's Disease Psychosis: Pimavanserin.
Topics: Alzheimer Disease; Antipsychotic Agents; Humans; Parkinson Disease; Psychotic Disorders; United Stat | 2023 |
Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review.
Topics: Antipsychotic Agents; Humans; Lewy Body Disease; Parkinson Disease; Piperidines; Psychotic Disorders | 2020 |
New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
Topics: Alzheimer Disease; Antipsychotic Agents; Anxiety; Humans; Piperidines; Psychotic Disorders; Quinolon | 2020 |
Dementia-related psychosis and the potential role for pimavanserin.
Topics: Dementia; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2022 |
Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Pi | 2017 |
Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Evidence-Based Medicine; Humans; Olanzapine; Parki | 2017 |
The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis.
Topics: Animals; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Quality of Life; Urea | 2017 |
Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden.
Topics: Antipsychotic Agents; Cost of Illness; Health Care Costs; Humans; Parkinson Disease; Piperidines; Ps | 2017 |
Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Topics: Antipsychotic Agents; Delusions; Drug Inverse Agonism; Hallucinations; Humans; Parkinson Disease; Pi | 2017 |
Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
Topics: Animals; Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Piperidines; Ps | 2018 |
Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Topics: Clinical Trials as Topic; Humans; Numbers Needed To Treat; Parkinson Disease; Piperidines; Psychotic | 2018 |
Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
Topics: Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic D | 2018 |
Pharmacological interventions for psychosis in Parkinson's disease patients.
Topics: Antipsychotic Agents; Clozapine; Dopamine; Humans; Parkinson Disease; Piperidines; Psychotic Disorde | 2018 |
Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
Topics: Alzheimer Disease; Clinical Trials as Topic; Dementia; Humans; Mental Status and Dementia Tests; Par | 2018 |
Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Topics: Antiparkinson Agents; Antipsychotic Agents; Consensus; Drug Substitution; Humans; Off-Label Use; Par | 2018 |
Pimavanserin for the treatment of Parkinson's disease psychosis.
Topics: Animals; Antiparkinson Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Serotoni | 2013 |
On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
Topics: Drug Discovery; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2014 |
Treating psychosis in movement disorder patients: a review.
Topics: Animals; Antipsychotic Agents; Clozapine; Humans; Movement Disorders; Piperidines; Psychotic Disorde | 2014 |
Pimavanserin.
Topics: Animals; Clinical Trials as Topic; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Sero | 2015 |
Pimavanserin for the treatment of Parkinson's disease psychosis.
Topics: Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Schizophrenia; Se | 2016 |
Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Humans; Molecular Targeted Therapy; Neur | 2016 |
11 trials available for urea and Psychoses
| Article | Year |
|---|---|
Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, | 2020 |
Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis.
Topics: Aggression; Alzheimer Disease; Double-Blind Method; Humans; Piperidines; Psychomotor Agitation; Psyc | 2020 |
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Age | 2021 |
Trial of Pimavanserin in Dementia-Related Psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Double-Blind Method; Female; Hallucinations | 2021 |
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; Female; Human | 2018 |
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; Female; Human | 2018 |
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; Female; Human | 2018 |
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; Female; Human | 2018 |
Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Female; Hum | 2018 |
Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; | 2019 |
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Antipsychotic Agents; Double-Blind Method; Female; | 2014 |
Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
Topics: Accidental Falls; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Drug T | 2015 |
Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Topics: Aged; Analysis of Variance; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Motor Acti | 2010 |
The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers.
Topics: Adolescent; Adult; Antipsychotic Agents; Biological Availability; Cross-Over Studies; Fasting; Food- | 2007 |
50 other studies available for urea and Psychoses
| Article | Year |
|---|---|
Pimavanserin and dementia-related psychosis.
Topics: Dementia; Humans; Piperidines; Psychotic Disorders; Urea | 2022 |
Pimavanserin for bipolar disorder.
Topics: Bipolar Disorder; Humans; Piperidines; Psychotic Disorders; Urea | 2022 |
Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT
Topics: Aged; Antipsychotic Agents; Humans; Parkinson Disease; Psychotic Disorders; Receptor, Serotonin, 5-H | 2022 |
Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries.
Topics: Aged; Antipsychotic Agents; Cohort Studies; Female; Humans; Male; Medicare; Parkinson Disease; Piper | 2022 |
The Therapeutic Potential of Pimavanserin in the Treatment of Hallucinogen Induced Psychosis and Persistent Perceptual Symptoms.
Topics: Hallucinogens; Humans; Piperidines; Psychotic Disorders; Urea | 2022 |
The Safety of Pimavanserin for Parkinson's Disease and Efforts to Reduce Antipsychotics for People With Dementia.
Topics: Antipsychotic Agents; Dementia; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2022 |
Halting the Metabolic Complications of Antipsychotic Medication in Patients with a First Episode of Psychosis: How Far Can We Go with the Mediterranean Diet? A Pilot Study.
Topics: Antipsychotic Agents; Diet, Mediterranean; Humans; Iron; Pilot Projects; Psychotic Disorders; Sodium | 2022 |
Halting the Metabolic Complications of Antipsychotic Medication in Patients with a First Episode of Psychosis: How Far Can We Go with the Mediterranean Diet? A Pilot Study.
Topics: Antipsychotic Agents; Diet, Mediterranean; Humans; Iron; Pilot Projects; Psychotic Disorders; Sodium | 2022 |
Halting the Metabolic Complications of Antipsychotic Medication in Patients with a First Episode of Psychosis: How Far Can We Go with the Mediterranean Diet? A Pilot Study.
Topics: Antipsychotic Agents; Diet, Mediterranean; Humans; Iron; Pilot Projects; Psychotic Disorders; Sodium | 2022 |
Halting the Metabolic Complications of Antipsychotic Medication in Patients with a First Episode of Psychosis: How Far Can We Go with the Mediterranean Diet? A Pilot Study.
Topics: Antipsychotic Agents; Diet, Mediterranean; Humans; Iron; Pilot Projects; Psychotic Disorders; Sodium | 2022 |
Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.
Topics: Aged; Antipsychotic Agents; Dementia; Humans; Levodopa; Parkinson Disease; Prospective Studies; Psyc | 2023 |
Design, Synthesis, Molecular Docking, and Biological Evaluation of Novel Pimavanserin-Based Analogues as Potential Serotonin 5-HT
Topics: Antipsychotic Agents; Drug Inverse Agonism; Humans; Molecular Docking Simulation; Psychotic Disorder | 2023 |
Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Female; Humans; Lewy Body Dise | 2019 |
The use of Pimavanserin in the treatment of Parkinson's disease: a consideration of its effects on sleep.
Topics: Cross-Sectional Studies; Genotype; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Slee | 2020 |
Pimavanserin: A 2019 Clarification on the FDA Update.
Topics: Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2019 |
Can G
Topics: Brain; GTP-Binding Protein alpha Subunits, Gq-G11; Humans; Piperidines; Psychotic Disorders; Recepto | 2020 |
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Female; Hallucinations; Humans; Male; Middle Aged; Pa | 2020 |
Treatment of Psychosis in Parkinson's disease and sudden death.
Topics: Antipsychotic Agents; Death, Sudden; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Ur | 2020 |
Pimavanserin in Dementia-Related Psychosis.
Topics: Dementia; Humans; Piperidines; Psychotic Disorders; Urea | 2021 |
Pimavanserin: A Friend or Foe in Parkinson Disease Psychosis.
Topics: Aged; Hospitalization; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2021 |
Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
Topics: Aged; Hospitalization; Humans; Medicare; Parkinson Disease; Piperidines; Psychotic Disorders; Retros | 2021 |
Pimavanserin and dementia-related psychosis: can HARMONY prevail?
Topics: Clinical Trials as Topic; Dementia; Humans; Piperidines; Psychotic Disorders; Urea | 2021 |
[Modern approaches to treatment of psychosis in Parkinson's disease].
Topics: Antiparkinson Agents; Antipsychotic Agents; Clozapine; Humans; Parkinson Disease; Piperidines; Psych | 2016 |
Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Drug-Related Side Effects and Adverse Reactions; Female | 2017 |
Pimavanserin for patients with Alzheimer's disease psychosis.
Topics: Alzheimer Disease; Double-Blind Method; Humans; Piperidines; Psychotic Disorders; Urea | 2018 |
Difficult choices in treating Parkinson's disease psychosis.
Topics: Antipsychotic Agents; Drug Approval; Humans; Off-Label Use; Parkinson Disease; Piperidines; Psychoti | 2018 |
Perspective on Pimavanserin and the SAPS-PD: Novel Scale Development as a Means to FDA Approval.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Drug Approval; Humans; Outcome Assessment, Health Ca | 2018 |
Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Parkinson Disease; | 2018 |
Psychiatric commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus".
Topics: Antipsychotic Agents; Consensus; Humans; Neurodegenerative Diseases; Off-Label Use; Parkinson Diseas | 2018 |
Neurological commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus".
Topics: Antipsychotic Agents; Consensus; Humans; Off-Label Use; Parkinson Disease; Piperidines; Psychotic Di | 2018 |
Can pimavanserin help patients with Parkinson disease psychosis?
Topics: Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 R | 2019 |
Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
Topics: Adult; Aged; Antipsychotic Agents; Clozapine; Delusions; Drug Resistance; Female; Hallucinations; Hu | 2019 |
Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Female; Humans; Male; Parkinson Disease; Piperidin | 2019 |
Pimavanserin for Parkinson Disease Psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disord | 2019 |
Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
Topics: Amphetamine; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Clozapine; Dopamine; | 2013 |
Pimavanserin as treatment for Parkinson's disease psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Female; Humans; Male; Parkinson Disease; Piperidines; Ps | 2014 |
Parkinson disease: Pimavanserin could be useful for treating psychosis in Parkinson disease.
Topics: Antiparkinson Agents; Antipsychotic Agents; Female; Humans; Male; Parkinson Disease; Piperidines; Ps | 2013 |
Pimavanserin: An Inverse Agonist Antipsychotic Drug.
Topics: Female; Humans; Male; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor | 2016 |
Pimavanserin (Nuplazid) for Parkinson's disease psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Drug Administration Schedule; Drug Costs; Drug Interacti | 2016 |
Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.
Topics: Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Receptor, | 2016 |
Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome.
Topics: Antiparkinson Agents; Antipsychotic Agents; Brain; Dopamine; Humans; Levodopa; Lewy Bodies; Parkinso | 2016 |
Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
Topics: Animals; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; S | 2017 |
Opposite roles of dopamine and orexin in quinpirole-induced excessive drinking: a rat model of psychotic polydipsia.
Topics: Animals; Benzoxazoles; Cerebral Cortex; Conditioning, Operant; Corticosterone; Disease Models, Anima | 2010 |
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System S | 2011 |
Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.
Topics: Alzheimer Disease; Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Disea | 2012 |
[First experience with an insulin-nadisan combination for hypoglycemia therapy in psychoses; preliminary report].
Topics: Convulsive Therapy; Electroconvulsive Therapy; Humans; Hyperinsulinism; Hypoglycemia; Insulin; Psych | 1956 |
[Hallucinations in chronic misuse of adaline; manifestations and clinical aspects of exogenic psychotic syndromes].
Topics: Bridged-Ring Compounds; Hallucinations; Humans; Mental Disorders; Piperidines; Psychotic Disorders; | 1956 |
URINARY EXCRETION OF BUFOTENIN-LIKE SUBSTANCE IN PSYCHOTIC PATIENTS.
Topics: 1-Propanol; Acetates; Alcohols; Alkaloids; Ammonia; Bufotenin; Chromatography; Hallucinogens; Humans | 1963 |
[Toxic psychoses due to sedormid, saridon and contra-pain].
Topics: Analgesics; Antipyrine; Caffeine; Drug Combinations; Humans; Hypnotics and Sedatives; Pain; Phenacet | 1950 |
[The blood-cerebrospinal fluid ratio of urea hypobromite in nervous and mental disease].
Topics: Anxiety; Blood; Language; Mental Disorders; Psychotic Disorders; Urea | 1950 |
Azotemia and psychosis.
Topics: Acute Kidney Injury; Adult; Anorexia Nervosa; Brain; Brain Injuries; Catatonia; Dehydration; Deliriu | 1967 |
[On the use of the testosterone blocking agent cyproterone acetate (SH 714) in hospitalized sex offenders and psychiatric patients. (Preliminary report)].
Topics: Adult; Aged; Aggression; Androgen Antagonists; Bilirubin; Enzymes; Epilepsy; Female; Homosexuality; | 1968 |
[TH therapy of climacteric disorders with a physiologic regulatory drug].
Topics: Bromides; Constipation; Diethylstilbestrol; Female; Humans; Menopause; Methyltestosterone; Middle Ag | 1966 |